AustriaAustria

f-star buys freedom

20.05.2008

Vienna – Austrian biotech company fstar GmbH has acquired future royalty obligations for its antibody engineering technology from New Century Pharmaceuticals (NCP) via a one-off payment. The Modular Antibody Technology was originally developed by Prof. Florian Rueker, one of f-star’s founders, in collaboration with NCP, a U.S. biopharmaceutical company. After f-star was set up, NCP became one of the company’s common shareholders, with rights to future royalty payments. In the course of this transaction, f-star has now bought back these royalty obligations with the help of TVM Capital, which acquired NCP’s minority stake in f-star.

AustriaAustria

08.03.2010

Vienna – GlaxoSmithKline, the se­cond largest drugmaker in the world, has closed its third drug development cooperation in Vienna in just over a year. After signing agreements with Intercell AG and Affiris GmbH, GSK is now to pay...

AustriaAustria

12.02.2010

Vienna – Austria-based Intercell AG yesterday announced that its first-in-man trial of the subunit vaccine IV47, designed to prevent infections from the majority of so Streptococcus pneumoniae serotypes, of which there are over...

AustriaAustria

01.02.2010

Vienna – Austrian-based biotech company f-star has closed an EUR8m extension to its Series A financing round. The investment was co-led by MP Healthcare Venture Management and Merck Serono Ventures. Existing investors Atlas...

AustriaAustria

01.02.2010

Vienna – With the naming of Beatrix Karl as the new Minister of Science, the Austrian government is complete. The 42 year-old legal scientist will follow pre­decessor Johannes Hahn, who has accepted a position as European...

AustriaAustria

01.02.2010

AustriaAustria

01.02.2010

Vienna – Austrian vaccine specialist Intercell and GlaxoSmithKline Biologicals SA (GSK) have formed a strategic alliance to commercialise needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine...

AustriaAustria

06.01.2010

Vienna – Austrian firm Intercell AG has initiated a phase II efficacy trial as part of its clinical development program for the investigational travellers’ diarrhoea (TD) vaccine in India. The primary objective of the field trial...

AustriaAustria

29.12.2009

Vienna – Austrian vaccine specialist Intercell AG is to expand the label of its vaccine Ixiaro/JEspect for Japanese encephalitis (JE). On Monday the company announced the start of a clinical phase III study for the travel...

Politics / Law, Miscellaneous, AustriaAustria

04.11.2009

Graz – Austria is likely to lead the EU’s efforts to integrate existing national biobanks and associated data throughout Europe into a European biobanking infrastructure. The resource is aimed at reaching critical mass for the...

AustriaAustria

21.09.2009

Vienna – Cardiovascular and inflammatory specialist Fibrex Medical has published positive Phase II results for FX06, a peptide for the treatment of reperfusion injury – damage to heart muscle that results from remedial treatment...

Displaying results 31 to 40 out of 116

< Previous 31-40 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/3/article/f-star-buys-freedom.html

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week

Products

Events

All Events

Partner-Events

Frankfurt am Main (DE)

ACHEMA 2015

Stock list

All quotes

TOP

  • CYTOS0.66 CHF6.45%
  • EVOLVA1.84 CHF5.14%
  • EPIGENOMICS5.55 EUR4.52%

FLOP

  • MEDIGENE8.43 EUR-3.77%
  • WILEX3.95 EUR-2.47%
  • BASILEA132.00 CHF-2.08%

TOP

  • 4SC4.65 EUR257.7%
  • SYNGENTA430.80 CHF31.8%
  • EVOLVA1.84 CHF21.1%

FLOP

  • CYTOS0.66 CHF-35.3%
  • MEDIGENE8.43 EUR-30.7%
  • CO.DON2.85 EUR-17.4%

TOP

  • WILEX3.95 EUR393.7%
  • 4SC4.65 EUR322.7%
  • FORMYCON28.39 EUR311.4%

FLOP

  • MOLOGEN5.05 EUR-53.4%
  • BIOFRONTERA2.29 EUR-24.9%
  • THERAMETRICS0.07 CHF-22.2%

No liability assumed, Date: 27.05.2015

Current issue

All issues